title: [Candida sp endocarditis. Experience in a third-level hospital and review of the literature].
abstract: Despite the relative high frequency of Candida bloodstream infection, Candida endocarditis is a rare entity. We report five cases of Candida endocarditis admitted to our hospital in the period between 2005 and 2011. Two cases were caused by C. albicans, two cases were caused by C. parapsilosis and in the last one, we didn't identify the species of Candida. All but one had clear risk factors for candidemia. Treatment consisted of amphotericin B with / without flucytosine in four patients, and they all underwent surgery for valve replacement and / or removal of intravascular devices. Overall mortality was 60% (40% of mortality was directly related to endocarditis). All patients who survived were given suppressive therapy with fluconazole for a minimum of two years.After stopping fluconazole there was a case of recurrence.
authors.affiliation: Servicio MI Infecciosas Hospital Universitario Virgen de la Arrixaca, Carretera Madrid- Cartagena, S/N. 30120. El Palmar, Murcia, Spain. maliht_1@hotmail.com
authors.forename: Alicia
authors.initials: A
authors.lastname: Hernández-Torres
authors.forename: Elisa
authors.initials: E
authors.lastname: García-Vázquez
authors.forename: Alicia
authors.initials: A
authors.lastname: Laso-Ortiz
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Herrero-Martínez
authors.forename: Joaquín
authors.initials: J
authors.lastname: Gómez-Gómez
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002175:Candida / Q000302:isolation & purification*; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology* / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000150:complications / Q000601:surgery; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D004696:Endocarditis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology* / Q000601:surgery; D017809:Fatal Outcome; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000150:complications; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012214:Rheumatic Heart Disease / Q000150:complications; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy; D013030:Spain / Q000453:epidemiology; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D000666:Amphotericin B; D015725:Fluconazole